Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04018963Unknown

The Impact of Endoscopic Pituitary Surgery on Nasal Function

Role: lead

NCT03717454Not ApplicableUnknown

Dopamine D2 Receptors(D2R) Imaging in Prolactinomas

Role: lead

NCT03714763Not ApplicableUnknown

Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)

Role: lead

NCT03400865Not ApplicableUnknown

Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas

Role: lead

NCT02536261Unknown

Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus

Role: lead

All 5 trials loaded